Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages

Table 5

Result of cox proportional hazard analysis for assessing risk factors of surgical failure at different stages of peripheral anterior synechiae.

Variables	PAS less than 50% ( eyes)				PAS more than 50% ( eyes)
	Univariate		Multivariate		Univariate
	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Preoperative PRP (versus not done)	0.34 (0.08–1.37)	0.130			0.51 (0.12–2.13)	0.354
Presence of NVA (versus absence)	0.39 (0.08–1.90)	0.242			NA
IVB group (versus control)	0.29 (0.08–1.10)	0.069			1.19 (0.37–3.81)	0.775
Number of IVB injection (per 1-time injection)	0.39 (0.15–1.06)	0.064	0.39 (0.15–1.06)	0.064	0.91 (0.51–1.61)	0.743
Baseline IOP (mmHg)	1.05 (0.98–1.13)	0.186			1.02 (0.95–1.09)	0.624
Baseline BCVA (LogMAR)	1.05 (0.89–1.88)	0.881			1.25 (0.56–2.78)	0.582

All 24 eyes had NVA. HR = hazard ratio; CI = confidence interval; NVA = neovascularization of angle; PAS = peripheral anterior synechiae; IVB = intravitreal bevacizumab; IOP = intraocular pressure; BCVA = best-corrected visual acuity; MAR = minimal angle of resolution; NA = nonapplicable. Variables with in univariate analysis were entered into multivariate analysis. Multivariate model using a backward elimination approach based on likelihood ratio; variables were entered in the model if and removed if in the saturated multivariate model.